Mergers and acquisitions in neurotechnology sector

Introduction

Mergers and acquisitions (M&A) in the neurotechnology sector refer to corporate transactions through which companies combine their businesses or acquire control over enterprises developing technologies related to the human brain, nervous system and neural functions. These technologies include brain-computer interfaces (BCIs), neural implants, neurostimulation devices, neurodiagnostic equipment, neurological software and artificial intelligence-based brain-monitoring systems.

Neurotechnology is increasingly used in the treatment and diagnosis of neurological conditions, rehabilitation, medical research and assistive communication. Consequently, companies operating in this sector attract investment from pharmaceutical businesses, medical-device manufacturers, technology corporations and healthcare institutions.

M&A transactions in this field raise distinctive legal concerns because acquired businesses may possess sensitive neural data, proprietary algorithms, medical-device patents and technologies capable of interacting directly with the human nervous system. Therefore, corporate consolidation must be examined not only under commercial and competition laws but also under privacy, medical-device, intellectual property and patient-protection frameworks.

Legal framework governing neurotechnology M&A in India

India does not currently have a separate statutory framework specifically governing mergers and acquisitions in neurotechnology. Such transactions are regulated through general corporate, competition, intellectual property, medical-device and data-protection laws.

1. Companies Act, 2013

Sections 230–232 regulate compromises, arrangements, mergers and amalgamations. The National Company Law Tribunal (NCLT) supervises relevant merger schemes and considers statutory requirements, shareholder interests and creditor protection.

Where a neurotechnology company is acquired through a share purchase or business transfer, the transaction must comply with applicable corporate governance, disclosure and approval requirements.

2. Competition Act, 2002

Sections 5 and 6 regulate combinations that may cause an appreciable adverse effect on competition in India. The Competition Commission of India (CCI) may examine acquisitions involving companies controlling important neurodiagnostic technologies, neural implant patents or specialised brain-computer interface platforms.

For example, an acquisition by a dominant medical-device manufacturer of a smaller company developing a competing neural implant could raise concerns about reduced innovation, restricted market access or elimination of potential competition.

3. Digital Personal Data Protection Act, 2023

Neurotechnology companies may process identifiable information obtained through brain-monitoring devices, neurological applications and clinical systems. Where such information qualifies as digital personal data, the DPDP Act may apply according to its scope and implementation.

Acquiring companies should examine the lawfulness of existing data collection, consent arrangements, security safeguards and proposed future processing. The Act does not create a separate statutory category of neural data, but identifiable neural information may fall within its general protection framework.

4. Patents Act, 1970

Neurotechnology businesses may own patents relating to neural implants, stimulation devices, diagnostic systems and associated technical processes. Patent ownership and licensing arrangements must be examined during due diligence.

Sections 68 and 69 are relevant to written assignments and registration of interests in patents. An acquisition agreement should clearly identify whether patents, software rights and research technologies are transferred or licensed.

5. Medical Devices Rules, 2017

Neurotechnology products that qualify as medical devices must comply with the applicable regulatory framework under the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017. The acquiring company should examine manufacturing licences, import permissions, product classifications, quality requirements and regulatory compliance records.

Due diligence in neurotechnology acquisitions

Due diligence is especially important because neurotechnology products may interact with sensitive biological systems and generate information about an individual's neurological activity.

The acquiring company should investigate:

Technical ownership: Patents, software, algorithms, research records and third-party licences.

Clinical evidence: Safety studies, clinical investigations and product-performance data.

Regulatory approvals: Medical-device licences, manufacturing permissions and compliance records.

Neural data protection: Consent, confidentiality, data security and permitted secondary uses.

Product liability: Claims arising from defective devices, inadequate warnings or negligent clinical use.

Cybersecurity: Vulnerabilities in connected neural devices and associated software.

Employment agreements: Confidentiality, invention ownership and obligations of specialist researchers.

Special attention should be given to implanted devices and connected systems because security weaknesses may create risks beyond ordinary commercial data breaches.

Protection of neural data and mental privacy

One of the most significant issues in neurotechnology M&A is the transfer and subsequent use of neural data. Brain-related information may reveal sensitive aspects of a person's neurological condition, cognitive activity or medical history.

An acquisition should not automatically be treated as permission to use all previously collected neural information for unrelated commercial purposes. The acquiring entity must examine applicable consent requirements, privacy obligations, contractual restrictions and the purpose for which the information was originally collected.

The Supreme Court's recognition of privacy as a fundamental right in India provides an important constitutional foundation for protecting mental privacy and personal autonomy.

Intellectual property and commercialisation

Neurotechnology acquisitions frequently involve the transfer of patents, proprietary software, technical designs and research databases. Parties must distinguish between ownership of intellectual property and permission to access or process personal data.

For example, a company may acquire ownership of a brain-computer interface platform without automatically acquiring unrestricted rights to use every patient's neural information collected through that platform.

Transaction documents should therefore contain clear provisions concerning:

Ownership of existing and jointly developed inventions.

Licensing of software and research technologies.

Confidentiality and restrictions on commercial use.

Ownership of improvements developed after acquisition.

Responsibility for existing intellectual property disputes.

Relevant judicial decisions

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms. The judgment is highly relevant to neurotechnology acquisitions because neural information may reveal intimate aspects of an individual's private life. Companies acquiring neurotechnology businesses must therefore consider privacy, autonomy and lawful data processing.

2. Selvi v. State of Karnataka (2010)

The Supreme Court held that involuntary narco-analysis, polygraph examinations and brain electrical activation profile tests violate constitutional protections against testimonial compulsion and personal liberty. The judgment is relevant to technologies that examine or infer information from brain activity. It establishes important limits on coercive neurological examination.

3. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court explained the requirements of valid informed consent in medical treatment. This principle is relevant to neurotechnology businesses developing devices or interventions that involve patients. Acquiring companies must examine whether clinical procedures and research activities were conducted with legally appropriate consent.

4. Competition Commission of India v. Thomas Cook (India) Ltd. (2018)

The Supreme Court considered the competition-law framework applicable to corporate restructuring and combinations. The decision provides relevant principles for understanding regulatory scrutiny of corporate transactions, including acquisitions involving neurotechnology enterprises.

5. Excel Crop Care Ltd. v. Competition Commission of India (2017)

The Supreme Court discussed competition-law principles and the assessment of penalties under the Competition Act. Although the case did not concern an acquisition, its principles are relevant when examining whether commercial arrangements following a neurotechnology merger could restrict competition.

Challenges and regulatory safeguards

The neurotechnology sector presents several challenges, including uncertain clinical outcomes, rapid technological development, cybersecurity risks, complex patent ownership and the absence of a dedicated Indian neurotechnology M&A framework.

Regulators and companies should therefore adopt safeguards such as independent technical audits, privacy impact assessments, verification of medical-device approvals and careful review of clinical research obligations. Merger agreements should also contain warranties concerning data protection, product safety, intellectual property ownership and regulatory compliance.

The CCI should examine whether acquisitions reduce competition or discourage independent innovation. Healthcare regulators should also ensure that corporate restructuring does not compromise patient safety or continuity of medical services.

Conclusion

Mergers and acquisitions in the neurotechnology sector create opportunities for scientific advancement, medical innovation and commercial growth. However, they also raise important concerns involving neural data protection, mental privacy, intellectual property, product safety and competition. In India, these transactions are governed by the Companies Act, 2013, Competition Act, 2002, Patents Act, 1970, Medical Devices Rules, 2017 and applicable data-protection legislation. The judgments in Puttaswamy, Selvi and Samira Kohli provide important constitutional and medical principles for protecting individuals during the development and commercialisation of neurotechnology. A balanced regulatory approach is essential to encourage innovation while preserving human dignity, autonomy and patient safety.